The Emerging Role of [89Zr]Zr-DFO-Girentuximab PET/ CT in Accurate Characterisation and Staging of ccRCC: early experience with three Patients

被引：0
|
作者：
Gelardi, F. [1 ,2 ]
Antunovic, L. [2 ]
Larcher, A. [1 ,2 ]
Musso, G. [1 ,2 ]
Re, C. [1 ,2 ]
Cei, F. [1 ,2 ]
Belladelli, F. [1 ,2 ]
Salonia, A. [1 ,2 ]
Luciano, R. [1 ,2 ]
Tenace, N. [1 ,2 ]
Olivieri, M. [1 ,2 ]
Savi, A. [2 ]
Sollini, M. [1 ,2 ]
Chiti, A. [1 ,2 ]
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-824
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 40 条
  • [21] 89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
    Verhoeff, Sarah R.
    van de Donk, Pim P.
    Aarntzen, Erik H. J. G.
    Oosting, Sjoukje F.
    Brouwers, Adrienne H.
    Miedema, Iris H. C.
    Voortman, Jens
    van Oordt, Willemien C. Menke -van der Houven
    Boellaard, Ronald
    Vriens, Dennis
    Slingerland, Marije
    Hermsen, Rick
    van Engen-van Grunsven, Ilse
    Heskamp, Sandra
    van Herpen, Carla M. L.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) : 1523 - 1530
  • [22] [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
    Florian Rosar
    Andrea Schaefer-Schuler
    Mark Bartholomä
    Stephan Maus
    Sven Petto
    Caroline Burgard
    Bastiaan M. Privé
    Gerben M. Franssen
    Yvonne H. W. Derks
    James Nagarajah
    Fadi Khreish
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 4736 - 4747
  • [23] [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
    Rosar, Florian
    Schaefer-Schuler, Andrea
    Bartholomae, Mark
    Maus, Stephan
    Petto, Sven
    Burgard, Caroline
    Prive, Bastiaan M.
    Franssen, Gerben M.
    Derks, Yvonne H. W.
    Nagarajah, James
    Khreish, Fadi
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (13) : 4736 - 4747
  • [24] 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma
    Hayne, Dickon
    Gauci, Richard
    Al-Zubaidi, Mohammed
    Viswambaram, Pravin
    McCombie, Steve P.
    Liow, Elizabeth Chien Hern
    Lenzo, Nat
    Ferguson, Thomas
    Antonini, Paola
    Meyrick, Danielle
    Hayward, Colin
    Redfern, Andrew David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] 89zirconium-labelled girentuximab (89zr-tlx250) pet in urothelial cancer patients (zipup) - a phase i trial of a novel staging modality for urothelial carcinoma
    Hayne, D.
    Gauci, R.
    Hawks, C.
    Al-Zubaidi, M.
    Viswambaram, P.
    Mccombie, S.
    Liow, E. C. H.
    Lenzo, N.
    Ferguson, T.
    Martina, S.
    Hayward, C.
    Redfern, A.
    EUROPEAN UROLOGY, 2023, 83 : S744 - S745
  • [26] 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP) - A novel diagnostic and staging modality for localized and metastatic urothelial carcinoma
    Viswambaram, Pravin
    Al-Zubaidi, Mohammed
    McCombie, Steve
    Gauci, Richard
    Liow, Elizabeth
    Ferguson, Thomas
    Redfern, Andrew
    Lenzo, Nat
    Hayne, Dickon
    BJU INTERNATIONAL, 2022, 129 : 167 - 168
  • [27] 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
    Al-Zubaidi, Mohammed
    Viswambaram, Pravin
    McCombie, Steve
    Liow, Elizabeth
    Lenzo, Nat
    Ferguson, Tom
    Redfern, Andrew D.
    Gauci, Richard
    Hayne, Dickon
    BMJ OPEN, 2022, 12 (04):
  • [28] Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer
    Burgard, Caroline
    Rosar, Florian
    Larsen, Elena
    Khreish, Fadi
    Linxweiler, Johannes
    Marlowe, Robert J.
    Schaefer-Schuler, Andrea
    Maus, Stephan
    Petto, Sven
    Bartholomae, Mark
    Ezziddin, Samer
    CANCER IMAGING, 2024, 24 (01)
  • [29] [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer (vol 47, pg 849, 2020)
    van Helden, E. J.
    Elias, S. G.
    Gerritse, S. L.
    van Es, S. C.
    Boon, E.
    Huisman, M. C.
    van Grieken, N. C. T.
    Dekker, H.
    van Dongen, G. A. M. S.
    Vugts, D. J.
    Boellaard, R.
    van Herpen, C. M. L.
    de Vries, E. G. E.
    Oyen, W. J. G.
    Brouwers, A. H.
    Verheul, H. M. W.
    Hoekstra, O. S.
    Menke-van der Houven van Oordt, C. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2481 - 2481
  • [30] [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis
    Florian Rosar
    Caroline Burgard
    Elena Larsen
    Fadi Khreish
    Robert J. Marlowe
    Andrea Schaefer-Schuler
    Stephan Maus
    Sven Petto
    Mark Bartholomä
    Samer Ezziddin
    Cancer Imaging, 24
1234